Zevra Therapeutics to Showcase Rare Disease Pipeline at H.C. Wainwright Conference

Event summary

  • Zevra Therapeutics will present at the H.C. Wainwright BioConnect Investor Conference on May 19, 2026, at 9:00 a.m. ET.
  • Executive leadership will hold one-on-one meetings with registered attendees.
  • The company focuses on rare disease therapies, with a lead product for Niemann-Pick disease type C (NPC).
  • Zevra aims to expand geographically and progress its late-stage pipeline.

The big picture

Zevra Therapeutics is positioning itself as a key player in the rare disease space, leveraging its commercial-stage foundation to drive pipeline progress and geographic expansion. The company’s focus on NPC therapy highlights its ability to bring specialized treatments to market, a critical differentiator in a competitive biopharmaceutical landscape. Investors will be watching how Zevra balances innovation with disciplined execution to deliver long-term value.

What we're watching

Pipeline Execution
How Zevra advances its late-stage pipeline toward key milestones will determine its long-term valuation.
Market Expansion
The pace at which Zevra broadens access through geographic expansion could impact revenue growth.
Investor Sentiment
Whether the conference presentation shifts market perception of Zevra’s strategic direction and execution.